On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells

Summary.  Background: That there is a correlation between cancer and procoagulant states is well‐known. C6 glioma cell line was originally induced in random‐bred Wistar–Furth rats and is morphologically similar to glioblastoma multiforme, the most common aggressive glioma resistant to therapeutic interventions. Objectives: In this study we analyzed the molecular mechanisms responsible for the highly procoagulant properties of C6 glioma cells. Methods: The presence of tissue factor (TF) and phosphatidylserine (PS) in C6 cells was investigated by flow‐cytometric and functional analyses. The assembly of extrinsic tenase, intrinsic tenase and prothrombinase complexes on these cells was studied using enzymatic assays employing plasma or purified proteins. Results: TF was identified by flow‐cytometric and functional [factor (F) Xa formation in the presence of cells and FVIIa] assays. Alternatively, conversion of FX into FXa was also observed in the presence of C6 cells, FIXa and FVIIIa. This effect was both cell‐ and FVIIIa‐dependent, being consistent with formation of the intrinsic tenase complex. C6 cells were also able to activate prothrombin in the presence of FXa and FVa, thus supporting formation of the prothrombinase complex. This ability was similar to positive controls performed with PS‐containing vesicles. Accordingly, exposure of PS on C6 cells was demonstrated by flow cytometry employing specific anti‐PS antibodies. In addition, annexin V, which blocks PS binding sites, inhibited FX and prothrombin conversion by their respective C6‐assembled activating complexes. Conclusion: C6 glioma cells support all procoagulant reactions leading to robust thrombin formation. This ability results from concomitant TF exposure and from the presence of the anionic lipid PS at the outer leaflet of cell membrane. Therefore, this animal cell line may be used to explore new aspects concerning the role of blood coagulation proteins in tumor biology, especially those affecting the central nervous system.

[1]  T. Schallert,et al.  The role of thrombin in gliomas , 2005, Journal of thrombosis and haemostasis : JTH.

[2]  C. Fadul,et al.  Coagulation biology in glioma pathogenesis: a missing link? , 2005, Journal of thrombosis and haemostasis : JTH.

[3]  M. Belting,et al.  Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[4]  Erwin G. Van Meir,et al.  PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. , 2005, Cancer research.

[5]  U. Pendurthi,et al.  Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. , 2004, Blood.

[6]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[7]  N. Tsopanoglou,et al.  Role of thrombin in angiogenesis and tumor progression. , 2004, Seminars in thrombosis and hemostasis.

[8]  Daniel J Brat,et al.  Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.

[9]  Xiaofeng Jiang,et al.  Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells , 2004, Journal of thrombosis and haemostasis : JTH.

[10]  Steven Patierno,et al.  Tissue factor, thrombin, and cancer. , 2003, Chest.

[11]  J. Kuratsu,et al.  The expression of tissue factor correlates with proliferative ability in meningioma. , 2003, Oncology reports.

[12]  Bert Grobben,et al.  Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion , 2002, Cell and Tissue Research.

[13]  D. Monroe,et al.  Platelets and thrombin generation. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[14]  B. Su,et al.  Tissue factor expression and angiogenesis in human glioma. , 2002, Clinical biochemistry.

[15]  K. Meehan,et al.  The coagulation system as a target for the treatment of human gliomas. , 2002, Seminars in thrombosis and hemostasis.

[16]  J. Morrissey,et al.  Tissue Factor: An Enzyme Cofactor and a True Receptor , 2001, Thrombosis and Haemostasis.

[17]  A. Falanga,et al.  Molecular basis for the relationship between thrombosis and cancer. , 2001, Thrombosis research.

[18]  M. Prins,et al.  Venous thromboembolism and occult malignancy. , 2001, Thrombosis research.

[19]  E. Holland,et al.  Glioblastoma multiforme: the terminator. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Nose,et al.  Tissue factor, osteopontin, αvβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression , 2000, British Journal of Cancer.

[21]  J. Ribeiro,et al.  Anophelin: kinetics and mechanism of thrombin inhibition. , 1999, Biochemistry.

[22]  K. Mann,et al.  Biochemistry and Physiology of Blood Coagulation , 1999, Thrombosis and Haemostasis.

[23]  V. Ramakrishnan,et al.  Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody (Mab COR7-6H9) , 1998, Journal of neurocytology.

[24]  Steven D. Carson,et al.  Tissue factor and cell morphology variations in cell lines subcloned from U87‐MG , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[25]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[26]  G. Reiser,et al.  Co-existence of two types of [Ca2+]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells , 1998, Neuroscience.

[27]  R. Ádány,et al.  Fibrin deposition in primary and metastatic human brain tumours. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  J. Kuratsu,et al.  Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.

[29]  J. S. Rao,et al.  Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis. , 1995, Neurosurgery.

[30]  M. Scully,et al.  Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[31]  Gordon Sg,et al.  Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. , 1993 .

[32]  S. Gordon,et al.  Three‐stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  J. Astermark,et al.  Effects of gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IX on factor X activation. Studies using proteolytic fragments of bovine factor IX. , 1992, The Journal of biological chemistry.

[34]  J. Chang,et al.  A novel one-step purification of human alpha-thrombin after direct activation of crude prothrombin enriched from plasma. , 1991, The Biochemical journal.

[35]  L. R. Wood,et al.  C6 glioma cell invasion and migration of rat brain after neural homografting: ultrastructure. , 1990, Neurosurgery.

[36]  A. Bezeaud,et al.  Interaction of human α‐thrombin and γ‐thrombin with antithrombin III, protein C and thrombomodulin , 1985 .

[37]  K. Mann,et al.  Tumor cell generation of thrombin via functional prothrombinase assembly. , 1985, Cancer research.

[38]  Ignacio Chávez,et al.  International Society on Thrombosis and Haemostasis , 1974 .

[39]  V. Rumjanek,et al.  Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. , 2005, Thrombosis research.

[40]  Masanori Kurimoto,et al.  Tissue Factor and Cancer Procoagulant Expressed by Glioma Cells Participate in their Thrombin-mediated Proliferation , 2004, Journal of Neuro-Oncology.

[41]  T. Schallert,et al.  A thrombin inhibitor reduces brain edema, glioma mass and neurological deficits in a rat glioma model. , 2003, Acta neurochirurgica. Supplement.

[42]  Mab COR7-6H.  Investigation of PAR-1-type thrombin receptors in rat glioma C6 cells with a novel monoclonal anti-PAR-1 antibody , 2022 .